$12.21
3.10% yesterday
Nasdaq, Dec 02, 10:00 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Stock price

$12.21
+0.22 1.83% 1M
+1.86 17.97% 6M
+4.48 57.96% YTD
+2.21 22.10% 1Y
-12.05 49.67% 3Y
-25.47 67.60% 5Y
-11.29 48.04% 10Y
-18.24 59.90% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.39 3.10%

Key metrics

Basic
Market capitalization
$618.1m
Enterprise Value
$343.9m
Net debt
positive
Cash
$274.2m
Shares outstanding
50.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.8 | 2.5
EV/Sales
2.1 | 1.4
EV/FCF
negative
P/B
3.8
Financial Health
Equity Ratio
55.7%
Return on Equity
-87.5%
ROCE
-38.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$161.3m | $248.3m
EBITDA
$-139.2m | $-30.5m
EBIT
$-154.9m | $-98.0m
Net Income
$-177.9m | $-130.8m
Free Cash Flow
$-106.3m
Growth (TTM | estimate)
Revenue
91.3% | 198.0%
EBITDA
39.3% | 85.8%
EBIT
37.0% | 57.5%
Net Income
25.5% | 42.4%
Free Cash Flow
42.5%
Margin (TTM | estimate)
Gross
87.2%
EBITDA
-86.3% | -12.3%
EBIT
-96.0%
Net
-110.3% | -52.7%
Free Cash Flow
-65.9%
More
EPS
$-3.4
FCF per Share
$-2.1
Short interest
11.4%
Employees
353
Rev per Employee
$240.0k
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a REGENXBIO, Inc. forecast:

17x Buy
89%
2x Hold
11%

Analyst Opinions

19 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
89%
Hold
11%

Financial data from REGENXBIO, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
161 161
91% 91%
100%
- Direct Costs 21 21
46% 46%
13%
141 141
207% 207%
87%
- Selling and Administrative Expenses 76 76
0% 0%
47%
- Research and Development Expense 219 219
2% 2%
136%
-139 -139
39% 39%
-86%
- Depreciation and Amortization 16 16
4% 4%
10%
EBIT (Operating Income) EBIT -155 -155
37% 37%
-96%
Net Profit -178 -178
25% 25%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Neutral
PRNewsWire
8 days ago
ROCKVILLE, Md. , Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference Fireside Chat: Tuesday, December 2 at 8:30 a.m.
Neutral
Seeking Alpha
27 days ago
REGENXBIO Inc. ( RGNX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Patrick Christmas - Executive VP & Chief Strategy and Legal Officer Curran Simpson - President, CEO & Director Steve Pakola - Executive VP & Chief Medical Officer Mitchell Chan - Executive VP & CFO Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Lili Nsongo - Leerink Pa...
Neutral
PRNewsWire
27 days ago
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed in October; confirmatory trial open and enrolling  New 12-month analysis shows all participants demonstrate improved functional outcomes across multiple natural history methods of measurement, when decline is expected Clemidsoge...
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 353
Founded 2008
Website regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today